6 O
ADVERSE O
REACTIONS O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
safety O
of O
INLYTA O
has O
been O
evaluated O
in O
715 O
patients O
in O
monotherapy O
studies O
, O
which O
included O
537 O
patients O
with O
advanced O
RCC B-Not_AE_Candidate
. O

The O
data O
described O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
reflect O
exposure O
to O
INLYTA O
in O
359 O
patients O
with O
advanced O
RCC B-Not_AE_Candidate
who O
participated O
in O
a O
randomized O
clinical O
study O
versus O
sorafenib O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
following O
risks O
, O
including O
appropriate O
action O
to O
be O
taken O
, O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1-5.13 O
) O
] O
: O
hypertension B-OSE_Labeled_AE
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
and O
fistula O
formation O
, O
thyroid B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
, O
RPLS B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
elevation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
and O
fetal B-OSE_Labeled_AE
development I-OSE_Labeled_AE
. O

EXCERPT O
: O
The O
most O
common O
( O
> O
=20 O
% O
) O
adverse O
reactions O
are O
diarrhea O
, O
hypertension O
, O
fatigue O
, O
decreased O
appetite O
, O
nausea O
, O
dysphonia O
, O
palmar-plantar O
erythrodysesthesia O
( O
hand-foot O
) O
syndrome O
, O
weight O
decreased O
, O
vomiting O
, O
asthenia O
, O
and O
constipation O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
, O
Inc O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
The O
median O
duration O
of O
treatment O
was O
6.4 O
months O
( O
range O
0.03 O
to O
22.0 O
) O
for O
patients O
who O
received O
INLYTA O
and O
5.0 O
months O
( O
range O
0.03 O
to O
20.1 O
) O
for O
patients O
who O
received O
sorafenib O
. O

Dose O
modifications O
or O
temporary O
delay O
of O
treatment O
due O
to O
an O
adverse O
reaction O
occurred O
in O
199/359 O
patients O
( O
55 O
% O
) O
receiving O
INLYTA O
and O
220/355 O
patients O
( O
62 O
% O
) O
receiving O
sorafenib O
. O

Permanent O
discontinuation O
due O
to O
an O
adverse O
reaction O
occurred O
in O
34/359 O
patients O
( O
9 O
% O
) O
receiving O
INLYTA O
and O
46/355 O
patients O
( O
13 O
% O
) O
receiving O
sorafenib O
. O

The O
most O
common O
( O
> O
=20 O
% O
) O
adverse O
reactions O
observed O
following O
treatment O
with O
INLYTA O
were O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dysphonia B-OSE_Labeled_AE
, O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
( I-OSE_Labeled_AE
hand I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
) I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
and O
constipation B-OSE_Labeled_AE
. O

Table O
1 O
presents O
adverse O
reactions O
reported O
in O
> O
=10 O
% O
patients O
who O
received O
INLYTA O
or O
sorafenib O
. O

Table O
1 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
Who O
Received O
INLYTA O
or O
Sorafenib O
Adverse O
Reaction O
[ O
note O
: O
Percentages O
are O
treatment-emergent O
, O
all-causality O
events O
] O
INLYTA O
Sorafenib O
( O
N=359 O
) O
( O
N=355 O
) O
All O
Grades O
[ O
note O
: O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
Version O
3.0 O
] O
Grade O
3/4 O
All O
Grades O
Grade O
3/4 O
% O
% O
% O
% O
Diarrhea B-OSE_Labeled_AE
55 O
11 O
53 O
7 O
Hypertension B-OSE_Labeled_AE
40 O
16 O
29 O
11 O
Fatigue B-OSE_Labeled_AE
39 O
11 O
32 O
5 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
34 O
5 O
29 O
4 O
Nausea B-OSE_Labeled_AE
32 O
3 O
22 O
1 O
Dysphonia B-OSE_Labeled_AE
31 O
0 O
14 O
0 O
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
27 O
5 O
51 O
16 O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
25 O
2 O
21 O
1 O
Vomiting B-OSE_Labeled_AE
24 O
3 O
17 O
1 O
Asthenia B-OSE_Labeled_AE
21 O
5 O
14 O
3 O
Constipation B-OSE_Labeled_AE
20 O
1 O
20 O
1 O
Hypothyroidism B-OSE_Labeled_AE
19 O
< O
1 O
8 O
0 O
Cough B-OSE_Labeled_AE
15 O
1 O
17 O
1 O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
15 O
1 O
12 O
1 O
Arthralgia B-OSE_Labeled_AE
15 O
2 O
11 O
1 O
Stomatitis B-OSE_Labeled_AE
15 O
1 O
12 O
< O
1 O
Dyspnea B-OSE_Labeled_AE
15 O
3 O
12 O
3 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
14 O
2 O
11 O
1 O
Headache B-OSE_Labeled_AE
14 O
1 O
11 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
13 O
1 O
14 O
1 O
Rash B-OSE_Labeled_AE
13 O
< O
1 O
32 O
4 O
Proteinuria B-OSE_Labeled_AE
11 O
3 O
7 O
2 O
Dysgeusia B-OSE_Labeled_AE
11 O
0 O
8 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
10 O
0 O
11 O
0 O
Dyspepsia B-OSE_Labeled_AE
10 O
0 O
2 O
0 O
Pruritus B-OSE_Labeled_AE
7 O
0 O
12 O
0 O
Alopecia B-OSE_Labeled_AE
4 O
0 O
32 O
0 O
Erythema B-OSE_Labeled_AE
2 O
0 O
10 O
< O
1 O
Selected O
adverse O
reactions O
( O
all O
grades O
) O
that O
were O
reported O
in O
< O
10 O
% O
of O
patients O
treated O
with O
INLYTA O
included O
dizziness B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
myalgia B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
dehydration B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
hemorrhoids B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
hematuria B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
tinnitus B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
lipase B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
glossodynia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
2 O
% O
) O
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
2 O
% O
) O
, O
hemoptysis B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( O
1 O
% O
) O
, O
retinal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
vein I-OSE_Labeled_AE
occlusion I-OSE_Labeled_AE
/thrombosis O
( O
1 O
% O
) O
, O
polycythemia B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Table O
2 O
presents O
the O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
reported O
in O
> O
=10 O
% O
patients O
who O
received O
INLYTA O
or O
sorafenib O
. O

Table O
2 O
. O

Laboratory O
Abnormalities O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
Who O
Received O
INLYTA O
or O
Sorafenib O
Laboratory O
Abnormality O
N O
INLYTA O
N O
Sorafenib O
All O
Grades O
[ O
note O
: O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
Version O
3.0 O
] O
Grade O
3/4 O
All O
Grades O
Grade O
3/4 O
% O
% O
% O
% O
ALP O
: O
alkaline O
phosphatase O
; O
ALT O
: O
alanine O
aminotransferase O
; O
AST O
: O
aspartate O
aminotransferase O
Hematology O
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
320 O
35 O
< O
1 O
316 O
52 O
4 O
Lymphocytes B-OSE_Labeled_AE
( I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
) I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
317 O
33 O
3 O
309 O
36 O
4 O
Platelets B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
312 O
15 O
< O
1 O
310 O
14 O
0 O
White B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
320 O
11 O
0 O
315 O
16 O
< O
1 O
Chemistry B-NonOSE_AE
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
336 O
55 O
0 O
318 O
41 O
< O
1 O
Bicarbonate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
314 O
44 O
< O
1 O
291 O
43 O
0 O
Hypocalcemia B-OSE_Labeled_AE
336 O
39 O
1 O
319 O
59 O
2 O
ALP B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
336 O
30 O
1 O
319 O
34 O
1 O
Hyperglycemia B-OSE_Labeled_AE
336 O
28 O
2 O
319 O
23 O
2 O
Lipase B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
338 O
27 O
5 O
319 O
46 O
15 O
Amylase B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
338 O
25 O
2 O
319 O
33 O
2 O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
331 O
22 O
< O
1 O
313 O
22 O
2 O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
331 O
20 O
< O
1 O
311 O
25 O
1 O
Hypernatremia B-OSE_Labeled_AE
338 O
17 O
1 O
319 O
13 O
1 O
Hypoalbuminemia B-OSE_Labeled_AE
337 O
15 O
< O
1 O
319 O
18 O
1 O
Hyperkalemia B-OSE_Labeled_AE
333 O
15 O
3 O
314 O
10 O
3 O
Hypoglycemia B-OSE_Labeled_AE
336 O
11 O
< O
1 O
319 O
8 O
< O
1 O
Hyponatremia B-OSE_Labeled_AE
338 O
13 O
4 O
319 O
11 O
2 O
Hypophosphatemia B-OSE_Labeled_AE
336 O
13 O
2 O
318 O
49 O
16 O
Selected O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
all O
grades O
) O
that O
were O
reported O
in O
< O
10 O
% O
of O
patients O
treated O
with O
INLYTA O
included O
hemoglobin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
above O
the O
upper O
limit O
of O
normal O
) O
( O
9 O
% O
for O
INLYTA O
versus O
1 O
% O
for O
sorafenib O
) O
and O
hypercalcemia B-OSE_Labeled_AE
( O
6 O
% O
for O
INLYTA O
versus O
2 O
% O
for O
sorafenib O
) O
. O

